Document Detail


Midtrimester pregnancy termination for fetal malformations. Use of intravaginal prostaglandin E2.
MedLine Citation:
PMID:  9284011     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare outcome differences and responses to treatment in pregnancies complicated by either major fetal malformations or previous fetal death in the second trimester. STUDY DESIGN: Data were analyzed from a computerized perinatal database and individual hospital records for singleton gestations between 14 and 23 weeks undergoing labor induction with prostaglandin E2 (PGE2) suppositories (20 mg intravaginally every three to five hours). RESULTS: Between January 1993 and June 1995, 65 pregnancies underwent induction of labor for either a lethal fetal malformation (38) or death (27). As compared with the fetal death group, the malformation group required more suppositories (median 4, range 1-10, versus median 3, range 1-6; P < .05) and needed a greater total dosage (77.5 +/- 38.5 mg versus 61.8 +/- 37.8 mg, P < .05). The mean time from initiation of treatment until delivery was two hours longer in the malformation group. There were no significant differences between the two treatment groups in incidence of maternal side effects or of retained placentas requiring operative intervention. CONCLUSION: Patients who undergo second-trimester induction of labor for major fetal malformations using intravaginal PGE2 should be counseled that the dosage of the drug is greater and that labor may last longer than in pregnancies complicated by a previous fetal death.
The capability to identify major fetal malformations in the middle trimester of pregnancy has increased the number of requests for late pregnancy termination. This retrospective study compared the use of prostaglandin E2 (PGE2) suppositories in 38 pregnancies undergoing induction of labor before 23 weeks of gestation after confirmation of 1 or more major fetal malformations and a control group of 27 pregnancies undergoing induction because of fetal death. Both groups were identified through a perinatal database of all pregnancies delivered at an Oklahoma City, Oklahoma, hospital in a 30-month period during 1992-94. The most frequent fetal malformations were cystic hygroma, spina bifida, hydrocephalus, and anencephaly. The median number of 20 mg PGE2 doses required was greater in the fetal malformation group (4, range 1-10) than the fetal death group (3, range 1-6). The total dosage was also greater for the malformation group (77.5 +or- 38.5 mg) than for the fetal death group (61.8 +or- 37.8 mg). Mean time until delivery was 2 hours less in the fetal death group, but the percentage of women delivering within 24 hours was similar in both groups (81.6% in the fetal malformation group and 85.2% in the fetal death group). All malformed fetuses were delivered stillborn. The frequencies of maternal side effects such as fever, vomiting, and diarrhea were somewhat greater in the fetal malformation group, presumably because of the higher dosage of PGE2. Although women undergoing second-trimester PGE2-induced labor for fetal malformations should be counseled that labor may last longer and a higher drug dosage may be required than in pregnancies complicated by fetal death, the method seems to be highly effective in both situations.
Authors:
D L Hagar; M T Valley; W F Rayburn; J C Carey
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of reproductive medicine     Volume:  42     ISSN:  0024-7758     ISO Abbreviation:  J Reprod Med     Publication Date:  1997 Aug 
Date Detail:
Created Date:  1997-10-09     Completed Date:  1997-10-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0173343     Medline TA:  J Reprod Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  497-500     Citation Subset:  IM; J    
Affiliation:
Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City 73190, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortion, Induced / methods*
Adult
Congenital Abnormalities*
Dinoprostone / administration & dosage*,  adverse effects
Female
Fetal Death
Humans
Placenta, Retained
Pregnancy
Pregnancy Trimester, Second
Treatment Outcome
Chemical
Reg. No./Substance:
363-24-6/Dinoprostone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carbohydrate metabolism. Evaluation in women with de novo hypertension in late pregnancy.
Next Document:  Pregnancy in infertile PCOD patients. Complications and outcome.